Neoreviews
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 8 No. 1, January 2007
Right arrow E-Letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinhorn, R. H
Right arrow Articles by Farrow, K. N
Right arrow Search for Related Content
PubMed
Right arrow Articles by Steinhorn, R. H
Right arrow Articles by Farrow, K. N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

NeoReviews Vol.8 No.1 2007 e14
© 2007 American Academy of Pediatrics

Pulmonary Hypertension in the Neonate

Robin H Steinhorn, MD*
Kathryn N Farrow, MD, PhD*

* Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Ill

Persistent pulmonary hypertensin of the newborn (PPHN), a major clinical problem in the neonatal intensive care unit, can contribute significantly to morbidity and mortality in both term and preterm infants. Hypoxemic respiratory failure or PPHN can place newborns at risk for death, neurologic injury, and other morbidities. PPHN is categorized into parenchymal lung disease (meconium aspiration syndrome, respiratory distress syndrome, sepsis), idiopathic (or "black-lung"), and pulmonary hypoplasia (as seen in congenital diaphragmatic hernia). Treatment involves correction of factors that may promote vasoconstriction, mechanical ventilation to achieve optimal lung volume that may include high-frequency oscillatory ventilation, medical optimization of cardiac output and left ventricular function, and inhaled nitric oxide. A number of alternative and emerging pulmonary vasodilators are being investigated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Academy of Pediatrics.